



8 12-09

JFW

MSB-7306

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Clark Pan, et al.

Serial No.: 10/799,897

Filed: March 12, 2004

Title: VPAC1 Selective Antagonists and Their Pharmacological Methods of Use

Commissioner for Patents
Alexandria, VA 22313-1450

Information Disclosure Statement

Dear Sir or Madam:

In order to comply with the discretionary regulations 37 CFR 1.97 and 1.98, attached hereto is Form PTO-1449, and copies of the documents listed thereon pursuant to 37 CFR 1.97. These documents contain information that the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited be given thorough consideration and that it be cited in the record of the prosecution history.

No representation is intended that the documents represent the results of a complete search. It is anticipated that the Examiner, in the normal course of examination, will make an independent search and determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b), and in the course of each search, will review for relevance each document cited in the attached form.

Respectfully submitted,

Aug. 10, 2004
Date

John W. Mahoney
John W. Mahoney
Reg. No. 44,892

Bayer Corporation
800 Dwight Way, P. O. Box 1986
Berkeley, California 94701
(510) 705-7725



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/799,897
	Filing Date	March 12, 2004
	First Named Inventor	Clark Pan
	Art Unit	Unknown
	Examiner Name	Unknown
Total Number of Pages in This Submission	Attorney Docket Number	MSB-7306

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. References 2. Return Acknowledgement Card
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	John W. Mahoney; Bayer Pharmaceuticals Corporation
Signature	<i>John W. Mahoney</i>
Date	Aug. 10 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Washington, DC 20231 on this date:

Typed or printed name	Luajuana LeGrande	Date	8-10-04
Signature	<i>Luajuana LeGrande</i>	Date	07/29/04 <i>LL</i>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. MSB-7306	SERIAL NUMBER 10/799,897
	APPLICANT: BAYER PHARMACEUTICALS CORPORATION	
	FILING DATE March 12, 2004	GROUP ART UNIT Unknown

/

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Miyata, A., Arimura, A., Dahl, R. R., Minamino, N., Uehara, A., Jiang, L., Culler, M. D., and Coy, D. H. (1989) <i>Biochem Biophys Res Commun</i> 164, 567-74.
2	Sherwood, N. M., Krueckl, S. L., and McRory, J. E. (2000) <i>Endocr Rev</i> 21, 619-70.
3	Laburthe, M., and Couvineau, A. (2002) <i>Regul Pept</i> 108, 165-173.
4	Gozes, I., Fridkin, M., Hill, J. M., and Brenneman, D. E. (1999) <i>Curr Med Chem</i> 6, 1019-34.
5	Reubi, J. C., Laderach, U., Waser, B., Gebbers, J. O., Robberecht, P., and Laissue, J. A. (2000) <i>Cancer Res</i> 60, 3105-12.
6	Moody, T. W., Hill, J. M., and Jensen, R. T. (2003) <i>Peptides</i> 24, 163-77.
7	Moody, T. W., Leyton, J., Coelho, T., Jakowlew, S., Takahashi, K., Jameison, F., Koh, M., Fridkin, M., Gozes, I., and Knight, M. (1997) <i>Life Sci</i> 61, 1657-66.
8	Rekasi, Z., Varga, J. L., Schally, A. V., Halmos, G., Groot, K., and Czompoly, T. (2000) <i>Proc Natl Acad Sci U S A</i> 97, 1218-23.
9	Plonowski, A., Varga, J. L., Schally, A. V., Krupa, M., Groot, K., and Halmos, G. (2002) <i>Int J Cancer</i> 98, 624-9.
10	Moody, T. W., Jensen, R. T., Fridkin, M., and Gozes, I. (2002) <i>J Mol Neurosci</i> 18, 29-35.
11	Moody, T. W., Zia, F., Draoui, M., Brenneman, D. E., Fridkin, M., Davidson, A., and Gozes, I. (1993) <i>Proc Natl Acad Sci U S A</i> 90, 4345-9.
12	Zia, H., Hida, T., Jakowlew, S., Birrer, M., Gozes, Y., Reubi, J. C., Fridkin, M., Gozes, I., and Moody, T. W. (1996) <i>Cancer Res</i> 56, 3486-9.
13	Zia, H., Leyton, J., Casibang, M., Hau, V., Brenneman, D., Fridkin, M., Gozes, I., and Moody, T. W. (2000) <i>Life Sci</i> 66, 379-87.
14	Moody, T. W., Leyton, J., Chan, D., Brenneman, D. C., Fridkin, M., Gelber, E., Levy, A., and Gozes, I. (2001) <i>Breast Cancer Res Treat</i> 68, 55-64.
15	Gelber, E., Granth, R., Fridkin, M., Dreznik, Z., Brenneman, D. E., Moody, T. W., and Gozes, I. (2001) <i>Cancer</i> 92, 2172-80.
16	Gourlet, P., De Neef, P., Cnudde, J., Waelbroeck, M., and Robberecht, P. (1997) <i>Peptides</i> 18, 1555-60.
17	Gourlet, P., Vandermeers, A., Vertongen, P., Rathe, J., De Neef, P., Cnudde, J., Waelbroeck, M., and Robberecht, P. (1997) <i>Peptides</i> 18, 1539-45.
18	Nicole, P., Lins, L., Rouyer-Fessard, C., Drouot, C., Fulcrand, P., Thomas, A., Couvineau, A., Martinez, J., Brasseur, R., and Laburthe, M. (2000) <i>J Biol Chem</i> 275, 24003-12.

PTO-1449 (Modified)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

19	Yung, S. L., Dela Cruz, F., Hamren, S., Zhu, J., Tsutsumi, M., Bloom, J. W., Caudle, M., Roczniak, S., Todd, T., Lemoine, L., MacDougall, M., Shanafelt, A. B., and Pan, C. Q. (2003) <i>J Biol Chem</i> 278, 10273-81.
20	Fry, D. C., Madison, V. S., Bolin, D. R., Greeley, D. N., Toome, V., and Wegrzynski, B. B. (1989) <i>Biochemistry</i> 28, 2399-409.
21	Inooka, H., Endo, S., Kitada, C., Mizuta, E., and Fujino, M. (1992) <i>Int J Pept Protein Res</i> 40, 456-64.
22	Theriault, Y., Boulanger, Y., and St-Pierre, S. (1991) <i>Biopolymers</i> 31, 459-64.
23	Wray, V., Kakoschke, C., Nokihara, K., and Naruse, S. (1993) <i>Biochemistry</i> 32, 5832-41

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	